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Abstract
Background: Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly
with antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated the anti-inflammatory
and neuroprotective properties of VCE-003.2, a quinone derivative of the non-psychotrophic phytocannabinoid
cannabigerol (CBG), which may derive its activity at the peroxisome proliferator-activated receptor-γ (PPARγ). The
compound is also an antioxidant.
Methods: We evaluated VCE-003.2 in an in vivo [mice subjected to unilateral intrastriatal injections of lipopolysaccharide
(LPS)] model of PD, as well as in in vitro (LPS-exposed BV2 cells and M-213 cells treated with conditioned
media generated from LPS-exposed BV2 cells) cellular models. The type of interaction of VCE-003.2 at the
PPARγ receptor was furtherly investigated in bone marrow-derived human mesenchymal stem cells (MSCs)
and sustained with transcriptional assays and in silico docking studies.
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Results: VCE-003.2 has no activity at the cannabinoid receptors, a fact that we confirmed in this study using
competition studies. The administration of VCE-003.2 to LPS-lesioned mice attenuated the loss of tyrosine
hydroxylase (TH)-containing nigrostriatal neurons and, in particular, the intense microgliosis provoked by LPS
in the substantia nigra, measured by Iba-1/Cd68 immunostaining. The analysis by qPCR of proinflammatory
mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and inducible nitric oxide synthase
(iNOS) in the striatum showed they were markedly elevated by the LPS lesion and strongly reduced by the
treatment with VCE-003.2. The effects of VCE-003.2 in LPS-lesioned mice implied the activation of PPARγ
receptors, as they were attenuated when VCE-003.2 was co-administered with the PPARγ inhibitor T0070907.
We then moved to some in vitro approaches, first to confirm the anti-inflammatory profile of VCE-003.2 in
cultured BV2 cells exposed to LPS. VCE-003.2 was able to attenuate the synthesis and release of TNF-α and IL-
1β, as well as the induction of iNOS and cyclooxygenase-2 (COX-2) elicited by LPS in these cells. However,
we found such effects were not reversed by GW9662, another classic PPARγ antagonist. Next, we investigated
the neuroprotective effects of VCE-003.2 in cultured M-213 neuronal cells exposed to conditioned media generated
from LPS-exposed cultured BV2 cells. VCE-003.2 reduced M-213 cell death, but again, such effects were not reversed by
T0070907. Using docking analysis, we detected that VCE-003.2 binds both the canonical and the alternative binding
sites in the PPARγ ligand-binding pocket (LBP). Functional assays further showed that T0070907 almost abolished
PPARγ transcriptional activity induced by rosiglitazone (RGZ), but it did not affect the activity of VCE-003.2 in a Gal4-Luc
system. However, T0070907 inhibited the effects of RGZ and VCE-003.2 on the expression of PPARγ-dependent genes
upregulated in MSCs.
Conclusions: We have demonstrated that VCE-003.2 is neuroprotective against inflammation-driven neuronal damage
in an in vivo model of PD and in in vitro cellular models of neuroinflammation. Such effects might involve PPARγ
receptors, although in silico and in vitro experiments strongly suggest that VCE-003.2 targets PPARγ by acting through
two binding sites at the LBP, one that is sensitive to T0070907 (canonical binding site) and other that is not affected by
this PPARγ antagonist (alternative binding site).
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Background
Inflammation is a key pathogenic event in Parkinson’s
disease (PD), so that anti-inflammatory strategies are
being investigated to limit neuronal deterioration in this
disease [1]. Certain cannabinoids have proved important
anti-inflammatory/neuroprotective properties, which
have been primarily assigned to the role exerted by the
cannabinoid receptor type-2 (CB2) in the control of
glia-dependent inflammatory events typical of neurode-
generative/neuroinflammatory disorders [2, 3]. However,
its relevance in PD has remained elusive for years. A few
years ago, Price and coworkers [4] described an elevation
of CB2 receptors in microglial cells recruited at the
lesion sites in mice intoxicated with MPTP, a model with
a modest glial response. These authors found that target-
ing these receptors reduced the damage of nigrostriatal
neurons [4], although a further study showed that the
inhibition of microglial activation and the preservation
of nigrostriatal dopaminergic neurons in MPTP-lesioned
mice involved surprisingly the activation of the canna-
binoid receptor type-1 (CB1) too [5]. In our laboratory,
we worked with postmortem basal ganglia collected
from PD patients and confirmed such upregulatory
response of CB2 receptors in glial elements [6]. We also
investigated the issue in an inflammatory model of
nigrostriatal damage consisting in intrastriatal injection
of lipopolysaccharide (LPS), in which we found elevated
levels of CB2 receptors in the basal ganglia [6, 7]. Such
receptors may be apparently located in activated glial
elements, although we did not investigate the cell
substrates in which this response takes place. In
addition, we found that CB2 receptor-deficient mice
were more vulnerable to LPS lesion than wild-type ani-
mals [6, 7], a difference that was not found in a model
with poor inflammatory responses, mice lesioned with
6-hydroxydopamine, in which the death of dopaminergic
neurons is related to mitochondrial dysfunction and
oxidative damage [7]. In agreement with this difference,
LPS-lesioned mice responded to compounds targeting
the CB2 receptor by preserving tyrosine hydroxylase
(TH)-containing neurons and by reducing microglial
reactivity and macrophage infiltration [6, 7]. In contrast,
6-hydroxydopamine-lesioned mice did not respond to
CB2 receptor activation [8]. Such differences were
recently confirmed by Concannon and coworkers [9]
who compared the elevation of CB2 receptors in LPS-
lesioned rats, which was paralleled by increased micro-
glial activation, with the poor response found in rodents
lesioned with 6-hydroxydopamine. However, work con-
ducted by Ternianov and coworkers [10] supported a role
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of CB2 receptors in 6-hydroxydopamine-lesioned mice
too, as they found that mice overexpressing CB2 receptors
were more protected against 6-hydroxydopamine-induced
nigrostriatal damage.
The anti-inflammatory potential of cannabinoids in
PD has been recently reinforced with the possibility that
some of them can also bind and activate specific
receptor types of the peroxisome proliferator-activated
receptor (PPAR) family such as PPARγ [11, 12]. Such
nuclear receptors have long been involved in the control
of neuroinflammatory responses [13], whereas specific
non-cannabinoid PPARγ activators (e.g., thiazolidine-
diones) have been found to be active in experimental
models of PD and have entered recently in clinical
investigation [14]. Some endocannabinoids (e.g., ananda-
mide and 2-arachidonoylglycerol) and their related
signaling lipids (e.g., palmitoylethanolamide, oleyletha-
nolamide), as well as different phytocannabinoids and
their derivatives, have been found to exert PPARγ-
mediated anti-inflammatory activity [12, 15, 16]. We
have recently designed, synthesized, and characterized
different phytocannabinoid derivatives, in particular a
series of quinone derivatives of cannabigerol (CBG) that
behave as PPARγ activators [17–19], while retaining the
lack of CB1/CB2 activity of their phytocannabinoid
template. For this study, we were particularly interested
in one non-thiophilic CBG quinone derivative, so-called
VCE-003.2, whose ability to activate PPARγ [19] enables
this compound to serve as an anti-inflammatory and a
neuroprotectant in LPS-lesioned mice, the experimental
model of PD that better reproduces inflammation as a
pathogenic event in this disease. We have investigated
VCE-003.2 in this in vivo PD model following previous
research conducted in murine models of Huntington’s
disease [19], which confirmed its activity at the PPARγ
and its capability to cross the blood-brain barrier after
systemic administration. In addition, we have extended
this research with some in vitro experiments useful to
confirm the anti-inflammatory profile of VCE-003.2
(cultured BV2 cells stimulated with LPS) or its neuro-
protective effects (cultured M-213 neuronal cells incu-
bated with conditioned media generated from cultured
BV2 cells stimulated with LPS). In all these experimental
approaches, the possible contribution of PPARγ activa-
tion has been investigated using selective inhibitors of
these nuclear receptors. However, the lack of activity of
classic PPARγ antagonists (e.g., T0070907, GW9662)
against VCE-003.2 effects in the in vitro studies and the
recent identification of a functional alternative binding
site for PPARγ ligands that does not overlap with the
canonical binding site used by glitazones [20] prompted
us to investigate whether VCE-003.2 binds to this
receptor at this different site using docking and
transcriptional analyses. In an additional experiment
presented as supplementary data (see Additional file 3),
we have also investigated whether the cannabinoid
receptor-independent antioxidant profile of VCE-003.2
enables this compound to also serve as neuroprotectant
in 6-hydroxydopamine-lesioned mice, which is
characterized, as mentioned above, by mitochondrial
dysfunction and oxidative stress but having a poor
inflammatory response. In this model, other antioxidant
phytocannabinoids (Δ9-tetrahydrocannabinol, cannabi-
diol, Δ9-tetrahydrocannabivarin) have been shown to
preserve nigrostriatal dopaminergic neurons by antioxi-
dant mechanisms independent of cannabinoid receptors
[7, 8, 21]. With this study in whole, we expect to add
experimental support to the idea that a pharmaceutical
formulation, using a pleiotropic cannabinoid derivative
targeting PPARγ receptors, and perhaps other relevant
targets for PD, may be of great interest to reduce inflam-
mation and oxidative stress, as well as to enhance
neuronal integrity in PD.
Methods
Synthesis and receptor characterization of VCE-003.2
The quinone derivative of CBG (6-(3,7)-dimethyl-octa-
2,6-dienyl)-5-hydroxy-3-pentyl-2-ethylamino-[1,4]benzo-
quinone), so-called VCE-003.2, was synthesized as
described previously [19]. Its activity as a PPARγ activa-
tor was also previously characterized [19]. To confirm
that, as expected, VCE-003.2 has no affinity at the CB1
and the CB2 receptors, we conducted radioligand
binding assays using membranes purified from cells
transfected with human CB1 or CB2 receptors
(RBHCB1M400UA and RBXCB2M400UA; Perkin-Elmer
Life and Analytical Sciences, Boston, MA, USA). The
protein concentration was 8 μg/well for the CB1 recep-
tor membranes and 4 μg/well for those of the CB2
receptor. The binding buffer was 50 mM Tris-Cl, 5 mM
MgCl2, 2.5 mM EDTA, and 0.5 mg/mL bovine serum
albumin (pH = 7.4) for CB1 and 50 mM TrisCl, 5 mM
MgCl2, 2.5 mM EGTA, and 1 mg/mL bovine serum
albumin (pH = 7.5) for CB2. The radioligand was [
3H]-
CP55940 (Perkin-Elmer) used at a concentration of
membrane KD × 0.8 nM, and the final incubation
volume was 200 μl for CB1 and 600 μl for CB2. Ninety-
six-well plates and the tubes necessary for the experi-
ment were previously siliconized with Sigmacote
(Sigma-Aldrich, Madrid, Spain). Membranes were
resuspended in the corresponding buffer and were
incubated (90 min at 30 °C) with the radioligand and
VCE-003.2 at a high concentration (40 μM) with the
purpose to determine the percentage of radioligand
displacement. Non-specific binding was determined with
10 μM WIN55212-2 and total radioligand binding by
incubation with the membranes in absence of VCE-
003.2. Filtration was performed by a Harvester®
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filtermate (Perkin-Elmer) with Filtermat A GF/C filters
pretreated with polyethylenimine 0.05%. After filtering,
the filter was washed nine times with a binding buffer
and dried and a melt-on scintillation sheet (Meltilex™ A,
Perkin-Elmer) was melted onto it. Then, radioactivity
was quantified by a liquid scintillation spectrophotom-
eter (Wallac MicroBeta Trilux, Perkin-Elmer). In the
case of both CB1- and CB2-transfected membranes, radi-
oligand displacement at these conditions was always
lower than 50%, then indicating negligible activity at
both cannabinoid receptor types with Ki values in the
micromolar range (> 40 μM; data from at least 3 experi-
ments performed in triplicate for each point).
Cultures of BV2 cells and M-213 neuronal cells
In a first experiment, mouse BV2 microglial cells (kindly
provided by Dr. Carmen Guaza, Instituto Cajal, CSIC)
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Lonza, Verviers, Belgium) supplemented with
10% fetal bovine serum (FBS, Sigma-Aldrich, Madrid,
Spain), 2 mM UltraGlutamine, and antibiotics (Lonza,
Verviers, Belgium) in a humidified atmosphere of 5%
CO2 at 37 °C. Cells were plated at a density of 45 × 10
4
cells per well in 12-well culture plates and incubated in
DMEM with a reduction of FBS to 1%. Three hours
later, cells were treated with 0.5 μg/ml LPS (from Escher-
ichia coli 055:B5, Sigma-Aldrich, Madrid, Spain), alone
or in combination with VCE-003.2, used at a concentra-
tion of 5 μM (selected from previous concentration–re-
sponse studies), and added 1 h before LPS. Twenty
hours after the addition of LPS, media were removed
and used for the analysis of tumor necrosis factor-α
(TNF-α) and interleukin-1β (IL-1β) levels using
commercial ELISA kits (ref. MTA00B, R&D Systems,
Minneapolis, MN, USA for TNF-α, and ref. MLB00C,
R&D Systems, Minneapolis, MN, USA for IL-1β),
whereas cell pellets were collected for analyzing protein
levels by the Lowry method, which were used to
normalize the cytokine data. In a follow-up experiment,
the procedure for cell plating, incubation, and treatment
with LPS and VCE-003.2 described above was repeated
again, but an additional experimental group consisting
of cells treated with LPS (0.5 μg/ml), VCE-003.2 (5 μM),
and GW9662 (10 μM; Abcam, Cambridge, UK) was
added. Twenty hours after the addition of LPS, cell
pellets were collected for the qPCR analysis of TNF-α,
IL-1β, inducible nitric oxide synthase (iNOS), and
cyclooxygenase-2 (COX-2).
In a second experiment, cultured BV2 cells were
maintained in DMEM (Lonza, Verviers, Belgium)
supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich, Madrid, Spain), 2 mM UltraGlutamine, and
antibiotics (Lonza, Verviers, Belgium) in a humidified
atmosphere of 5% CO2 at 37 °C. For experiments, cells
were plated at a density of 2 × 105 cells per well in 6-well
culture plates and incubated in DMEM with a reduction
of FBS to 1%. Three hours later, cells were treated with
0.5 μg/ml LPS (from Escherichia coli 055:B5, Sigma-
Aldrich, Madrid, Spain). Twenty-four hours after the
addition of LPS, media were removed to be added to
cultures of the rat M-213 striatal cell line (kindly
provided by Dr. WJ Freed, National Institute on Drug
Abuse, Bethesda, MD, USA) to induce cell death follow-
ing a procedure described previously [22]. To this end,
M-213 cells were maintained in DMEM supplemented
with 10% FBS, 2 mM UltraGlutamine, and 1% antibiotics
(Lonza, Verviers, Belgium) under a humidified 5% CO2
atmosphere at 37 °C. For cytotoxicity experiments, cells
were seeded at 50,000 cells/well in 24-well plates and
maintained under a humidified atmosphere (5% CO2) at
37 °C overnight. Afterwards, normal medium was
completely replaced by the conditioned media generated
in BV2 cell experiments, and then, M-213 cells were
treated with the vehicle (0.1% DMSO) or with three
different concentrations of VCE-003.2 (0.1, 0.5, and
1 μM; selected according to our previously published
study [19], which described an IC50 = 1.2 μM for the
binding of VCE003.2 to PPARγ receptors), added alone
or combined with the selective PPARγ inhibitor
T0070907 (10 μM; Cayman Chemical, Ann Arbor,
Michigan, USA). Rosiglitazone (RGZ) (20 μM, according
to [23] and laboratory experience; Sigma-Aldrich,
Madrid, Spain) was also added, alone or combined with
T0070907 (10 μM), as a positive control for PPARγ
activation. Cells were incubated for 40 h before the
neuronal death was analyzed with the MTT assay
(Panreac AppliChem., Barcelona, Spain). The data were
normalized in relation with a control group consisting in
M-213 cells exposed to conditioned media generated by
BV2 cells in absence of LPS.
Mesenchymal stem cell differentiation
Human mesenchymal stem cells (MSCs) derived from bone
marrow were obtained as previously described [19]. Cells
were seeded in α-MEM containing 15% FCS, 2 mM Ultra-
Glutamine, 1 ng/ml bFGF, and antibiotics, and adipogenic
differentiation was performed as described [19]. Treatment
with RGZ (1 μM) and VCE-003.2 (1 μM) in the presence
and the absence of T0070907 (5 μM) started at the same
time as the differentiation process. After a week of differenti-
ation, the mRNA expression for PPARγ isoform 2 (PPARγ2),
lipoprotein-lipase (LPL), CCAAT/enhancer-binding protein-
α (CEBPA), adiponectin (ADIPOQ), and fatty acid-binding
protein 4 (FABP4) was analyzed as described [19].
PPARγ transcriptional assays
To analyze PPARγ transcriptional activity, HEK-293T
cells were cultured in 24-well plates and transiently
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co-transfected with the expression vector GAL4-PPARγ
and the luciferase reporter vectors GAL4-luc (firefly lu-
ciferase) and pRL-CMV (renilla luciferase) using Roti©-
Fect (Carl Roth, Karlsruhe, Germany). After stimulation,
the luciferase activities were quantified using Dual-
Luciferase Assay (Promega, Madison, WI, USA).
Immunoblotting
Whole cell extracts were obtained by lysing the cells in
NP-40 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl,
10% glycerol, and 1% NP-40) supplemented with
protease and phosphatase inhibitors. Lysate concentra-
tions were determined by the Bradford assay (Bio-Rad
Laboratories, Hercules, CA, USA). Proteins (30 μg/lane)
were separated by SDS-PAGE, transferred onto PVDF
membranes, and blocked with PBS-T (PBS + 0.1%
Tween-20) containing 5% non-fat dry milk for 30 min at
room temperature. Incubation with anti-PPARγ (ref.
C26H12, Cell Signaling Technology, Beverly, MA, USA)
and anti-α-actin (ref. AC-74, Sigma-Aldrich, Madrid,
Spain) was performed overnight at 4 °C, and washed
membranes were incubated with appropriate secondary
antibodies coupled to horseradish peroxidase that were
detected by an enhanced chemiluminescent reagent.
Animals and surgical lesions
Male C57BL/6 mice were housed in a room with a con-
trolled photoperiod (06:00–18:00 light) and temperature
(22 ± 1 °C). They had free access to standard food and
water and were used at adult age (3- to 4-month-old;
25–30 g weight). All experiments were conducted ac-
cording to European guidelines (directive 2010/63/EU)
and approved by the “Comité de Experimentación
Animal” of our university (ref. CEA-UCM 56/2012). For
in vivo experiments, mice were anesthesized (ketamine
40 mg/kg + xylazine 4 mg/kg, i.p.) and subjected to uni-
lateral injections of S. Minnesota LPS (Sigma-Aldrich,
Madrid, Spain) into two points of the right striatum fol-
lowing the procedure developed by Hunter et al. [24].
We used the following stereotaxic coordinates from
bregma: + 1.18 mm AP, − 1.5 mm ML, and − 3.5 mm
DV, as well as − 0.34 mm AP, − 2.5 mm ML, and −
3.2 mm DV (see details in [24]). At each intrastriatal
coordinate, 5 μg of LPS in a volume of 1 μl of saline was
injected slowly (0.5 μl/30 s) and the needle was left in
place for 5 min before being slowly withdrawn. This
avoids generating reflux and a rapid increase in intracra-
nial pressure. Controls were sham-operated and injected
with 1 μl of saline using the same coordinates. After the
application of LPS or saline, mice were also subjected to
pharmacological treatments as described in the following
section. The lesions were generated using unilateral
administration, the advantage of which is that
contralateral structures serve as controls for the different
analyses.
Pharmacological treatments and sampling
LPS-lesioned mice were distributed in three groups and
administered i.p. with 10 mg/kg of VCE-003.2, alone or
in combination with 5 mg/kg of the PPARγ antagonist
T0070907 (Cayman Chemical, Ann Arbor, Michigan,
USA) [25] or vehicle [DMSO (3.3%) + Tween 20 (2%) +
saline (94.7%)]. The experiment included a fourth group
consisting of sham-operated mice also treated with
DMSO-Tween 20-saline. The treatment was initiated
approximately 16 h after the LPS lesion and was
repeated daily for 21 days. One day after the last injec-
tion, mice were killed by rapid and careful decapitation
and their brains were rapidly removed and frozen in
2-methylbutane cooled in dry ice and stored at − 80 °C
for subsequent immunohistochemical analysis in the
substantia nigra and qPCR analysis in the striatum.
Real-time qRT-PCR analysis
Brain coronal slices (around 500 μm thick) were made at
levels containing the striatum, according to Palkovits
and Brownstein Atlas [26]. Subsequently, such structure
was dissected and used for qRT-PCR analysis. Cell
pellets from the in vitro experiments were also used for
qRT-PCR analysis. Total RNA was isolated from the
different samples using SurePrep RNA/Protein Purifica-
tion Kit (Fisher Bioreagents, Madrid, Spain). The total
amount of RNA extracted was quantitated by spectrom-
etry at 260 nm and its purity from the ratio between the
absorbance values at 260 and 280 nm. After genomic
DNA was removed (to eliminate DNA contamination),
single-stranded complementary DNA was synthesized
from up to 1 μg of total RNA using the commercial kits
Rneasy Mini Quantitect Reverse Transcription (Qiazen,
Hilgen, Germany) and iScript™ cDNA Synthesis Kit
(Bio-Rad, Hercules, CA, USA). The reaction mixture
was kept frozen at − 20 °C until enzymatic amplification.
Quantitative RT-PCR assays were performed using Taq-
Man Gene Expression Assays (Applied Biosystems,
Foster City, CA, USA) to quantify mRNA levels for
TNF-α (ref. Mm99999068_m1), IL-1β (ref. Mm00
434228_m1), iNOS (ref. Mm01309902_m1), and COX-2
(ref. Mm00478372_m1), using GAPDH expression (ref.
Mm99999915_g1) as an endogenous control gene for
normalization. The PCR assay was performed using the
7300 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA), and the threshold cycle (Ct) was
calculated by the instrument’s software (7300 Fast
System, Applied Biosystems, Foster City, CA, USA).
Expression levels were calculated using the 2−ΔΔCt
method.
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Immunohistochemical procedures
Brains were sliced in coronal sections (containing the
substantia nigra) in a cryostat (30 μm thick) and col-
lected on antifreeze solution (glycerol/ethylene glycol/
PBS; 2:3:5) and stored at − 20 °C until used. Sections
were mounted on gelatin-coated slides and, once
adhered, washed in 0.1 M potassium PBS (KPBS) at pH
7.4. Then, endogenous peroxidase was blocked by 30-min
incubation at room temperature in a peroxidaseblocking
solution (Dako Cytomation, Glostrup, Denmark). After
several washes with KPBS, sections were incubated
overnight at room temperature with the following primary
antibodies: (i) rabbit polyclonal anti-TH (Chemicon-
Millipore, Temecula, CA, USA) used at 1/400; (ii)
rabbit polyclonal anti-Iba-1 antibody (Wako Chemicals,
Richmond, VA, USA) used at 1/300; or (iii) monoclonal
rat anti-mouse Cd68 antibody (AbD Serotec, Oxford,
UK) used at 1/200. Dilutions were carried out in KPBS
containing 5% normal horse serum and 0.1% Triton X-
100 (Sigma Chem., Madrid, Spain). After incubation,
sections were washed in KPBS, followed by incubation
with the corresponding biotinylated secondary antibody
(1/400) (Vector Laboratories, Burlingame, CA, USA)
for 1 h at room temperature. Avidin–biotin complex
(Vector Laboratories, Burlingame, CA, USA) and 3,3′-
diaminobenzidine substrate–chromogen system (Dako
Cytomation, Glostrup, Denmark) were used to obtain a
visible reaction product. Negative control sections were
obtained using the same protocol with omission of the
primary antibody. A Leica DMRB microscope and a
DFC300FX camera (Leica, Wetzlar, Germany) were
used for the observation and photography of the slides,
respectively. For quantification of the intensity of TH,
Iba-1, or CD68 immunostaining either in the substantia
nigra (both ipsilateral and contralateral sides), we used
the NIH Image Processing and Analysis software
(ImageJ; NIH, Bethesda, MD, USA) using 4–5 sections,
separated approximately by 200 μm, and observed with
× 5–20 objectives depending on the method and the
brain area under quantification. In all sections, the
same area of the substantia nigra pars compacta was
analyzed. Analyses were always conducted by experi-
menters who were blinded to all animal characteristics.
Data were expressed as percentage of immunostaining
intensity in the ipsilateral (lesioned) side over the
contralateral (non-lesioned) side.
Immunofluorescence was used for a double-labeling
analysis with TH and Cd68 in sections containing the
substantia nigra pars compacta. After pre-incubation for
20 min with Tris-buffered saline with 1% Triton X-100
(pH 7.5), sections were sequentially incubated overnight
at 4 °C with a monoclonal rat anti-mouse Cd68 antibody
(AbD Serotec, Oxford, UK) used at 1/200, followed by
washing in a Tris-buffered saline and a new incubation
(at 37 °C for 2 h) with an anti-rat secondary antibody
made in donkey (1/200) conjugated with Alexa 488 (Life
Technologies-Thermofisher Scientific, Waltham, MA,
USA) rendering green fluorescence. Sections were then
washed again and incubated overnight at 4 °C with a
polyclonal rabbit anti-TH (Chemicon-Merck Millipore,
Darmstadt, Germany) used at 1/200, again followed by
washing in a Tris-buffered saline and a new incubation
(at 37 °C for 2 h) with an anti-rabbit secondary antibody
made in goat (1/200) conjugated with Alexa 546
(Invitrogen, Carlsbad, CA, USA) rendering red fluores-
cence. Sections were counter-stained with nuclear stain
TOPRO-3-iodide (Molecular Probes, Eugene, OR, USA)
to visualize cell nuclei. A SP5 Leica confocal microscope
was used for slide observation and photography.
Docking analysis
Ligand docking was performed using the AutoDock4
[27] and the Vina software [28] with the virtual screen-
ing tools PyRx [29] and PyMOL [30]. The receptor
model used was the PDB reference (RCSB Protein Data
Bank accession code) 2Q59 and 3B0R [20], and 4EMA
[31]. The search space for the docking, around the
receptor molecule surface, was set according to previous
findings about several binding sites for different ligands.
Once analysis has been performed, AutoDock Vina
provides the estimated binding affinity value, which is
the sum of the intermolecular energy, due to the inter-
action between both molecules, and the torsional free-
energy penalty, due to the conformation adopted by
these molecules to properly fit the interaction surface. A
negative value indicates that the bond is thermodynam-
ically stable, whereas a positive value means instability.
Search space for the docking was set around the binding
sites described previously [20].
Data analysis
Data were subjected to the one-way analysis of variance
followed by the Student–Newman–Keuls, Tukey, or the
Bonferroni multiple comparison tests.
Results
Determination of CB1/CB2 receptor binding for VCE-003.2
VCE-003.2 was synthesized as described in a previous
study [19], in which its pharmacodynamic properties, in
particular its activity as a PPARγ activator, were already
investigated using transcriptional assays [19]. VCE-003.2
is a derivative of CBG, a non-psychoactive cannabinoid
present in the Cannabis plant that does not exhibit any
activity at the CB1 receptor [32]. We have recently con-
firmed that CBG binds the CB2 receptor also with a
poor affinity in the micromolar range [17]. Therefore, it
was expected that its quinone derivative VCE-003.2 has
no affinity at both CB1 and CB2 receptors. To confirm
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that, we conducted radioligand binding assays using
membranes purified from cells transfected with human
CB1 or CB2 receptors. Our data demonstrated that a
high concentration of VCE-003.2 (40 μM) displaced
radioligand binding to both CB1 and CB2 receptors with
a percentage in both cases lower than 50%, then indicat-
ing negligible affinity for both receptors with predicted
Ki always > 40 μM in both cases.
Anti-inflammatory and neuroprotective effects of VCE-003.2
in LPS-lesioned mice
Given the activity of VCE-003.2 at the PPARγ receptors,
which is an important factor involved in the control of
inflammation, we wanted to evaluate its anti-
inflammatory/neuroprotective properties in a typically in
vivo inflammatory model of PD, LPS-lesioned mice. It is
likely that, in the absence of CB2 receptor activity for
VCE-003.2, such beneficial effects, if they exist, should
be possibly mediated by enhancing PPARγ signaling.
First, we analyzed TH immunostaining in the substantia
nigra pars compacta and demonstrated a reduction of
immunoreactivity in LPS-lesioned mice (F(3,17) = 5.21,
p < 0.05; see Fig. 1) in concordance with the previous
data [6, 7], and evident here comparing the lesioned
ipsilateral side with the non-lesioned contralateral side
(Fig. 1). In addition to these quantitative data, the mor-
phological analysis of the immunostained substantia
nigra showed an evident reduction in neuropil (Fig. 1),
possibly reflecting neurite losses in nigral neurons. The
reduction in immunoreactivity levels and also the deteri-
orated aspect of neuropil in nigral neurons were
reversed by the treatment with VCE-003.2 (Fig. 1). In
addition, we also found a lowering effect of VCE-003.2
on the intense microgliosis provoked by LPS and
revealed by Iba-1 (F(3,18) = 6.76, p < 0.005; see Fig. 2)
and Cd68 (F(3,19) = 5.03, p < 0.05; see Fig. 3) immuno-
staining in the substantia nigra. Such microgliosis was
evident not only by the elevated immunoreactivity but
also by the presence of microglial cells (labeled with
Iba-1) with ameboid aspect (activated state) compared
with the ramified form (quiescent state) currently found
in controls (Fig. 2). The treatment with VCE-003.2
changed this activated morphology towards a classic
resting aspect (Fig. 2). In addition, using a double im-
munofluorescence analysis for TH and Cd68, we con-
firmed that this reactive microgliosis was specifically
located inside and surrounding the substantia nigra pars
compacta and associated with the loss of TH-positive
neurons. This analysis is presented as a supplementary
figure (see Additional file 1) and demonstrates the prox-
imity of TH and Cd68 labeling, but the expected lack of
any overlapping.
We also analyzed by qPCR several proinflammatory
markers typical of the activated microglial cells recruited
Fig. 1 Intensity of the immunostaining for TH (bottom right panel) measured in a selected area of the substantia nigra pars compacta of adult
male mice at 3 weeks of being subjected to an intrastriatal injection of LPS and daily treated with VCE-003.2 (10 mg/kg), alone or combined with
T0070907 (5 mg/kg), or vehicle. Immunoreactivity values are measures in the lesioned side over the non-lesioned side and correspond to means
± SEM of 4–6 subjects per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05
versus vehicle-treated control mice). Representative immunostaining images for each experimental group, with indication of the approximate area
quantified, are shown in the top and left panels (scale bar = 100 μm)
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Fig. 2 Intensity of the immunostaining for Iba-1 (bottom right panel) measured in a selected area of the substantia nigra pars compacta of adult male
mice at 3 weeks of being subjected to an intrastriatal injection of LPS and daily treated with VCE-003.2 (10 mg/kg), alone or combined with T0070907
(5 mg/kg), or vehicle. Immunoreactivity values are measures in the lesioned side over the non-lesioned side and correspond to means ± SEM of 4–6
subjects per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05, **p < 0.01 versus
vehicle-treated control mice; #p < 0.05 versus VCE-003.2-treated LPS-lesioned mice). Representative Iba-1 immunostaining images for each experimental
group are shown in the top and left panels (scale bar = 100 μm), including a specific inlet showing the morphological characteristics of Iba-1-labeled
cells (scale bar = 25 μm)
Fig. 3 Intensity of the immunostaining for Cd68 (left panel) measured in a selected area of the substantia nigra pars compacta of adult male
mice at 3 weeks of being subjected to an intrastriatal injection of LPS and daily treated with VCE-003.2 (10 mg/kg), alone or combined with
T0070907 (5 mg/kg), or vehicle. Immunoreactivity values are measures in the lesioned side over the non-lesioned side and correspond to means
± SEM of 4–6 subjects per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05,
**p < 0.01 versus vehicle-treated control mice). Representative Cd68 immunostaining images for each experimental group are shown in the right
panels (scale bar = 100 μm)
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at the lesioned ipsilateral striatum, always compared to
the non-lesioned contralateral side. As expected, we
detected a strong elevation in the expression of two pro-
inflammatory cytokines TNF-α (F(3,19) = 4.375, p < 0.05;
Fig. 4) and IL-1β (F(3,19) = 6.472, p < 0.005; Fig. 4), as
well as in the proinflammatory enzyme iNOS (F(3,19) =
6.808, p < 0.005; Fig. 4) in the striatum of LPS-lesioned
mice, all of them compatible with the microglial activa-
tion found in these mice (Figs. 2 and 3). The elevation in
iNOS was attenuated by the treatment with VCE-003.2,
with differences between vehicle- and VCE-003.2-treated
LPS-lesioned mice being statistically significant (Fig. 4).
Moreover, the treatment of LPS-lesioned mice with VCE-
003.2, although did not reach a statistically significant
difference compared to vehicle-treated LPS-lesioned
animals in TNF-α and IL-1β, provoked that the values for
both cytokines are no longer statistically different com-
pared to control mice, thus supporting a modest but
evident effect (Fig. 4).
The most interesting was that these effects and also
those observed with VCE-003.2 on the microglial acti-
vation (Iba-1 and Cd68 immunostaining) disappeared
when the CBG derivative was co-administered with the
PPARγ antagonist T0070907 (Figs. 2, 3, and 4), then
supporting the involvement of this nuclear receptor in
VCE-003.2 effects. The only effect of VCE-003.2 that
was not reversed by T0070907 in a statistically signifi-
cant manner was the recovery in TH immunostaining,
although the pattern of changes showed the expected
tendency (Fig. 1). It is also important to remark that, in
some cases, e.g., Iba-1 and Cd68 immunostaining and
IL-1β and iNOS gene expression, the values reached
after the blockade of PPARγ receptors in VCE-003.2-
treated LPS-lesioned mice were even elevated when
compared to the vehicle-treated LPS-lesioned mice
(Figs. 2, 3, and 4). This may suggest the existence of an en-
dogenous basal tone activating PPARγ, whose apparent
beneficial effects would be eliminated only when these re-
ceptors are blocked. Such idea would be concordant with
previous data showing that GW9662, another irreversible
PPARγ inhibitor, was toxic for dopaminergic neurons in
MPTP-treated mice [33].
This evaluation of the neuroprotective effects of VCE-
003.2 in in vivo models of PD also included experiments
in an additional model of parkinsonism, mice lesioned
with 6-hydroxydopamine, which, contrarily to LPS-
lesioned mice, is a model with poor inflammation and
glial reactivity and mainly based on oxidative stress
derived from mitochondrial dysfunction. These data are
presented as a supplementary material (see Additional file 3).
Anti-inflammatory effects of VCE-003.2 against a LPS
insult in cultured BV2 cells
Next, we used some in vitro approaches to further inves-
tigate the benefits found with VCE-003.2 in the inflam-
matory in vivo model of PD. We investigated first the
anti-inflammatory profile of VCE-003.2 in cultured BV2
cells exposed to LPS. On the one hand, VCE-003.2 was
able to attenuate the LPS-induced release of TNF-α
(F(2,43) = 104.4, p < 0.0001; Fig. 5) and reduced the p
values compared to controls in the case of IL-1β (F(2,44)
= 18.72, p < 0.0001; Fig. 5), with both cytokines being
measured in culture media using ELISA kits. On the other
hand, this was associated with similar changes measured
by qPCR in cell pellets, with elevations after LPS which
were attenuated after the treatment with VCE-003.2 for
TNF-α (F(3,27) = 8.327, p < 0.001; Fig. 6) and for two
proinflammatory enzymes like COX-2 (F(3,27) = 16.10, p
< 0.0001; Fig. 6) and iNOS (F(3,27) = 35.95, p < 0.0001;
Fig. 6). Again, in the case of IL-1β (F(3,27) = 5.05, p < 0.01;
Fig. 6), the effect of VCE-003.2 consisted in a reduction in
p values compared to controls (Fig. 6). However, these
effects of VCE-003.2 effects were not inhibited by the
PPARγ antagonist GW9662; in fact, they were apparently
Fig. 4 mRNA levels for TNF-α, IL-1β, and iNOS in the striatum of adult male mice at 3 weeks of being subjected to an intrastriatal injection of LPS and
daily treated with VCE-003.2 (10 mg/kg), alone or combined with T0070907 (5 mg/kg), or vehicle. Values are the ratio between the lesioned side and
the non-lesioned side and correspond to means ± SEM of 4–6 subjects per group. Data were assessed by the one-way analysis of variance followed by
the Student–Newman–Keuls test (*p < 0.05, **p < 0.01 versus vehicle-treated control mice; #p < 0.05 versus VCE-003.2-treated LPS-lesioned mice)
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enhanced in the presence of this antagonist (Fig. 6). We
do not believe that this result may be due to the change in
the PPARγ antagonist because, as mentioned above,
GW9662 is other synthetic irreversible PPARγ antagonist,
which, as T0070907, covalently binds to Cys285 into the
PPARγ ligand-binding pocket (LBP). The only difference
between both antagonists is a single nitrogen substitution,
so that both compounds can be indistinctly used as a tool
to investigate PPARγ activation by different ligand activa-
tors. Hence, the fact that the effects of VCE-003.2 were
not reversed by GW9662, which would presumably occur
with T0070907 too, might indicate that, in LPS-treated
BV2 cells, VCE-003.2 might act also through PPARγ-
independent mechanisms, and this may be the conse-
quence of the well-known LPS-induced downregulation of
these receptors found in BV2 cells [34] and also in macro-
phages [35]. However, we do not believe that this may
happen in our study, as we have evidence that both RGZ
and VCE-003.2 increase the expression of PPARγ, which,
in general, is known to be upregulated by PPARγ ligand
agonists, counteracting the repressive effect of LPS on the
expression of this nuclear receptor (see Additional file 2).
As regards the enhancing action of GW9662 on VCE-
003.2 effects in LPS-treated BV2 cells, we believe that they
may be related to an additive interaction of both at the
PPARγ LBP derived from a potential activity of GW9662
as partial agonist too. This has been previously described
for different biological activities of this class of antagonists
[36, 37], whereas, in our hands, both GW9662 and
T0070907 exert PPARγ transcriptional activity in a Gal4-
Luc system, although to a much lesser extent than RGZ
and VCE-003.2 (data not shown).
Neuroprotective effects of VCE-003.2 in M-213 neuronal
cells exposed to conditioned media generated by cultured
BV2 cells exposed to LPS
The second in vitro approach we used to further explore
the neuroprotective properties of VCE-003.2 in PD
consisted in investigating its capability to protect
cultured M-213 neuronal cells against death induced by
exposure to conditioned media generated from cultured
BV2 cells overexposed to LPS. This is a classic method
to investigate neuroprotection against inflammation-
driven neurotoxicity [22]. First, we wanted to evaluate
different concentrations of VCE-003.2 and what we
found was the classic dual effect of cannabinoids, with
low concentrations (0.1–0.5 μM) preserving M-213 cells
against the inflammatory insult, to a similar extent than
RGZ used as a positive control for PPARγ, whereas
higher concentrations, but not particularly high (1 μM),
resulted toxic (F(9,38) = 24.95, p < 0.0001; Fig. 7). This
was mostly similar to the results found with VCE-003.2
in cultured neural progenitor cells, in which toxicity was
evident from a concentration of 2 μM [19]. The three
Fig. 5 Levels of TNF-α and IL-1β measured in the media of cultured
BV2 cells exposed to LPS (0.5 μg/ml) in the presence or absence of
VCE-003.2 (5 μM). Values are means ± SEM of at least 4 independent
experiments each performed in triplicate. Data were assessed by the
one-way analysis of variance followed by the Student–Newman–Keuls
test (**p < 0.01, ***p < 0.005 versus control cells (no treated with LPS);
###p < 0.005 versus cells treated with LPS)
Fig. 6 mRNA levels for TNF-α, IL-1β, COX-2, and iNOS measured in the cell pellets of cultured BV2 cells exposed to LPS (0.5 μg/ml) in the presence or
absence of VCE-003.2 (5 μM) and/or GW9662 (10 μM). Values are means ± SEM of at least 7 independent experiments each performed in duplicate.
Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05, **p < 0.01, ***p < 0.005 versus control
cells (no treated with LPS); #p < 0.05, ###p < 0.005 versus cells treated with LPS)
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concentrations of VCE-003.2 and RGZ were examined
also in the presence of the PPARγ receptor inhibitor
T0070907 in order to determine whether their effects
were mediated by activation of these receptors. However,
whereas the effect of RGZ was completely reversed by
the PPARγ receptor inhibitor T0070907, this inhibitor
was inactive against the effect of VCE-003.2 at the two
protective concentrations (Fig. 7), then suggesting the
contribution of mechanisms other than the canonic acti-
vation of PPARγ in these effects. The same happened
with the toxic concentration (Fig. 7).
VCE-003.2 binds to the canonical and alternative sites in
the PPARγ LBP
We have previously shown that VCE-003.2 is a PPARγ
partial agonist compared to RGZ [19]. PPARγ receptor
ligands can induce a graded response such as full and
partial agonism and antagonism that may depend on the
mode of interaction and binding to the LBP [20, 38].
Thus, we were interested to study the potential func-
tionality of the canonical and alternative PPARγ sites
involved in the response to VCE-003.2. Luciferase
reporter assays were used to measure PPARγ-dependent
transcription, and RGZ (F(13,28) = 84.77, p < 0.0001;
Fig. 8a) and VCE-003.2 (F(13,35) = 15.41, p < 0.005;
Fig. 8b) showed increase in PPARγ transactivation. To
study the participation of the alternative binding site, the
cells were pre-incubated with T0070907 before treating
the cells with the agonist ligands. T0070907 did not
block the action of VCE-003.2 (Fig. 8b), but it was very
effective to block RGZ-induced PPARγ transactivation
(Fig. 8a) that is consistent with the fact that RGZ acti-
vates PPARγ by acting mainly through the canonical
binding site [20]. To further analyze the effects of VCE-
003.2 at this nuclear receptor, we studied the behavior of
this compound in the presence of RGZ. To achieve this,
GAL4-PPARγ/GAL4-luc co-transfected cells were pre-
incubated with increasing concentrations of VCE-003.2,
then treated with 1 μM RGZ. VCE-003.2 did not affect
RGZ-induced PPARγ transactivation, thus suggesting
that VCE-003.2 does not compete with RGZ for the
same binding site at the LBP PPARγ (Fig. 8c).
Next, we also studied the action of VCE-003.2 in
MSCs, which is a valid cell model to assess endogenous
PPARγ function related to adipogenic differentiation.
MSCs were differentiated to adipocytes in the presence
of VCE-003.2 or RGZ with or without T0070907 for
7 days, as reflected the data of mRNA expression for the
PPARγ-dependent genes PPARγ2, LPL, CEBPA, ADI-
POQ, and FABP4 analyzed by RT-PCR. In the absence
of an antagonist, both RGZ [PPARγ2: F(3,8) = 67.85, p <
0.0001; LPL: F(3,8) = 114.4, p < 0.0001; CEBPA: F(3,8) =
27.37, p = 0.0005; ADIPOQ: F(3,8) = 491.1, p < 0.0001;
FABP4: F(3,8) = 50.45, p < 0.0001; Fig. 8d] and VCE-
003.2 [PPARγ2: F(3,8) = 67.85, p < 0.0001; LPL: F(3,8) =
63.38, p < 0.001; CEBPA: F(3,8) = 16.29, p < 0,005;
ADIPOQ: F(3,8) = 24.67, p = 0.0016; FABP4: F(3,8) =
50.45, p < 0.0001; Fig. 8e] upregulated the expression of
these adipogenic-related genes, although to a different
extent, thus confirming the differences between a full
PPARγ agonist (RGZ) and a PPARγ modulator (VCE-
003.2) [19]. T0070907 abrogate the effects of both RGZ
(Fig. 8d) and VCE-003.2 (Fig. 8e) on the expression of
PPARγ-dependent genes, indicating that VCE-003.2 is
also functional through the canonical LBP.
To confirm the ability of VCE-003.2 to adopt different
binding modes, we performed docking simulation stud-
ies using crystal structures 3B0R, 4EMA, and 2Q59 de-
posited in the Protein Data Bank (PDB). Molecular
docking demonstrated that VCE-03.2 molecule binds to
the hydrophobic core within the 11-helix bundle (canon-
ical site) and also to the side of the Ω loop β3-β4 region
in Helix 3 (alternative binding site). Moreover, in the
presence of GW9662, VCE-003.2 only binds to the alter-
native site by interacting with Ser342 in the Ω loop β3
and Gly284 in Helix 3 (Fig. 9).
Fig. 7 Cell viability measured in cultured M-213 cells treated with
different concentrations of VCE-003.2 (0.1, 0.5, and 1.0 μM) or RGZ
(20 μM) in the presence or the absence of T0070907 (10 μM) and
exposed to conditioned media generated from LPS-stimulated BV2
cells. The control (100% of cell viability) consisted in M-213 cells that
were exposed to conditioned media in the absence of LPS. Values
are means ± SEM of at least 4 independent experiments each
performed in duplicate. Data were assessed by the one-way analysis
of variance followed by the Student–Newman–Keuls test (*p < 0.05,
**p < 0.01, ***p < 0.005 compared to the control cells (incubated with
conditioned media no generated with LPS); @p < 0.05, @@p < 0.01
versus cells treated with RGZ, as well as versus cells treated with
VCE-003.2 (0.1 and 0.5 μM) combined or not with T0070907 (incubated
with conditioned media generated with LPS))
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Discussion
Whether neuroinflammation and microglia activation is
a consequence or a cause of nigral cell deterioration and
death in PD has been a controversial issue for years.
However, it appears that presently, there is a general
consensus about the important pathogenic role played
by glial activation in this disease [39], with increasing
evidence supporting that glia-driven inflammation
contributes to the progressive degeneration of nigral
dopaminergic neurons even in early phases of PD in
patients [40]. Such situation may be experimentally
reproduced using LPS insults into the nigrostriatal area
[24], but it can be also found in other experimental
models of PD [41] and identified in postmortem PD
brains at autopsy [42]. In addition, epidemiological data
support that the regular use of non-steroidal anti-
inflammatory drugs (e.g., ibuprofen) reduces the risk of
developing PD [43], a fact that gives an instrumental
value to the control of inflammation in PD. Based on
this idea, different anti-inflammatory agents have been
investigated, at preclinical and even clinical levels, with
variable success in PD. This includes inhibitors of iNOS
or COX-2, non-steroidal anti-inflammatory drugs, the
antibiotic minocycline, piaglitazone and other PPARγ
activators, purinergic P2X receptor antagonists, and
immunosuppressants [39, 42].
Cannabinoids have been also investigated for the
reduction of inflammatory events in PD using mainly
selective CB2 receptor agonists [2, 44]. The rationale to





Fig. 8 Effects of T0070907 on RGZ- and VCE-003.2-induced PPARγ transcriptional activity and MSCs differentiation. HEK-293T cells were transiently
transfected with PPARγ-GAL4 plus GAL4-luc, pre-incubated with T0070907 (5 μM) for 15 min and then treated with increasing concentrations of
either RGZ (a) or VCE-003.2 (b) for 6 h and luciferase activity measured in the cell lysates (open circles, PPARγ ligand; dark circles, PPARγ ligand
plus T0070907). c Cells were transfected with the same pair of plasmids and treated with RGZ, VCE-003.2, or a combination of both compounds
for 6 h and luciferase activity measured in the cell lysates. T0070907 prevented d RGZ- and e VCE-003.2-induced adipogenic differentiation in
MSCs. The cells were differentiated in AM in the presence of RGZ and VCE-003.2 in the absence and the presence of T0070907, and adipogenic
markers were characterized. Gene expression of adipogenic markers such as PPARγ2, LPL, FABP4, CEBPA, and ADIPOQ were measured after 7 days
of differentiation. Data were assessed by the one-way analysis of variance followed by the Tukey test (*p < 0.05, **p < 0.01, ***p < 0.001 RGZ or
VCE-003.2 compared to the control cells; ##p < 0.01, ###p < 0.001 RGZ or VCE-003.2 + T0070907 compared to RGZ- or VCE-003.2-treated cells)
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elicited by these receptors, predominantly in microglial
cells and infiltrated macrophages recruited at the CNS areas
lesioned in PD [4, 6], as well as on the anti-inflammatory
and neuroprotective effects derived from the selective activa-
tion of these upregulated receptors [4, 6, 7, 9]. However,
another line of evidence may derive from the possibility to
target PPARγ receptors with certain cannabinoids in PD.
Such evidence is based on (i) the relevant role played by
these nuclear receptors in the control of inflammation in
numerous pathological conditions [45, 46]; (ii) the well-de-
scribed PPARγ-mediated anti-inflammatory activity of cer-
tain cannabinoids in different models of central and
peripheral inflammation [11]; and (iii) the effects of non-
cannabinoid PPARγ activators (e.g., thiazolidinediones [14])
in PD. PPAR receptors function as lipid sensors forming het-
erodimers with the retinoic acid X receptor and binding to
regulatory DNA elements so-called peroxisome proliferator
response elements (PPREs), then regulating transcription of
a wide range of genes [47]. The three different PPAR iso-
types (-α, -β/δ, and -γ) are expressed in all cell types in the
brain [48, 49], and all of them, by functioning in an inte-
grated manner as a complex system, so-called the PPAR
triad, have been reported to have neuroprotective properties
(reviewed recently in [47]).
In the present study, we attempted to activate PPARγ
receptors using a CBG derivative, VCE-003.2, which has
been previously found to be partial agonist at these
receptors, and to investigate its potential in experimental
models of PD. Thus, VCE-003.2 was investigated in a
classic inflammatory rodent model of PD generated by
intrastriatal application of LPS. This insult enhances re-
active microgliosis, reflected by elevated Iba-1 and Cd68
immunostaining in the substantia nigra, in parallel to an
elevation in the expression of proinflammatory markers
in the striatum, including the cytokines TNF-α and IL-
1β, and, in particular, iNOS. This is a pro-inflammatory
enzyme which has been found to strongly contribute to
deteriorate neuronal homeostasis in PD in conditions of
reactive gliosis [50–52], a fact reflected in the loss of
TH-positive neurons found here. We previously reported
that the same proinflammatory markers were strongly
elevated by the LPS insult and such elevations were
partially reversed by the selective activation of CB2
receptors [6]. Using VCE-003.2, which does not activate
CB2 receptors, we found the same response, reduction
in the microglial reactivity in the substantia nigra and a
marked reduction in the toxicity generated by these
activated glial cells, which is reflected in the low levels
of proinflammatory markers measured in the striatum of
those LPS-lesioned animals treated with VCE-003.2.
Such beneficial effects influenced the loss of TH-positive
neurons in the substantia nigra, which was partially
reduced. Our study also confirmed the involvement of
an activation of PPARγ signaling in VCE-003.2 effects in
LPS-lesioned mice, so in conditions of elevated glial
reactivity and local inflammatory events. Such conclu-
sion derives from the observation that the improvements
reached with this CBG derivative in reactive microgliosis
Fig. 9 PPARγ LBD structures 3B0R, 4EMA, and 2Q59 bound to VCE-003.2 (yellow) with and without of GW9662 (orange). Binding of VCE-003.2 to
the alternative binding site through Ser342 in the Ω loop β3 for crystals 4EMA (Ki = 2.11 μM), 2Q59 (Ki = 2.24 μM), and 3B0R (358.38 nM). In the
presence of GW9662, VCE-003.2 binds to G284 of Helix 3 and Ser342 on the Ω loop and GW9662 binds to the canonical LPB site (Ki for VCE-003.2
= 711.27 nM). Analysis of VCE-003.2 binding to the canonical LBP site by interacting with Ser289 (2Q59: Ki for VCE-003.2 = 1.49 μM), R288 (3B0R: Ki
for VCE-003.2 = 3.21 μM), and H449 (4EMA, Ki for VCE-003.2 = 607.81 nM) on Helix 11
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and the expression of proinflammatory markers
disappeared when PPARγ receptors were blocked with a
selective inhibitor that interacts with the canonical
PPARγ LBP. Even, in some cases, the levels of reactive
microgliosis and proinflammatory events appeared to be
much higher after the blockade of PPARγ receptors, thus
indicating the possible existence of an intrinsic endogen-
ous activity of these nuclear receptors limiting inflam-
matory events that would disappear after the blockade
with T0070907. A similar response was found in the
study with VCE-003.2 conducted in experimental models
of Huntington’s disease [19]. In this sense, it has been
shown that endogenous fatty acid ligands such as
15d-PGJ2 and 5-oxo-ETE covalently bind to Cys285 in
the PPARγ LBP and its transcriptional activities can be
inhibited by T0070907 [53]. Thus, it is conceivable that
in brain inflammatory conditions, some eicosanoids are
produced to limit neuronal damage, and therefore,
blocking this protective response would result in a more
exacerbated damage.
Our in vivo study in LPS-lesioned mice was followed
by investigation of the anti-inflammatory and neuropro-
tective properties of VCE-003.2 in a couple of in vitro
experimental approaches using cultured LPS-exposed
BV2 cells, alone or in combination with M-213 neuronal
cells. Our objective was to confirm and, eventually,
further explore in vitro the VCE-003.2-induced reduc-
tion in the LPS-induced generation of proinflammatory
mediators, an objective that was completely attained
with the first of the two in vitro approaches. Using only
these microglia-related cells, we observed the expected
increase in TNF-α, IL-1β, COX-2, and iNOS elicited by
persistent exposure to LPS, which has been previously
reported in other studies [54] and how VCE-003.2 was
able, in general, to attenuate these responses. The
second in vitro approach used in this study was aimed at
confirming the capability of VCE-003.2 to protect
neurons against glia-driven inflammatory insults. We
generated conditioned media from cultured BV2 cells
overexposed to LPS and added these media to cultured
M-213 neuronal cells in combination with VCE-003.2 to
determine its effects on cell viability. Again, VCE-003.2,
used at low concentrations, was able to provide
neuroprotection. We found that the in vitro anti-
inflammatory, neuroprotective, and transcriptional (see
below) activities of VCE-003.2 were not inhibited by
either GW9662 or T0070907, which are PPARγ antago-
nists commonly used to discriminate between PPARγ-
dependent and PPARγ-independent activities. However,
this assumption is no longer valid, as there is evidence
of alternative binding sites in the PPARγ LBP that are
functional and not affected by this class of PPARγ antag-
onists. Indeed, our docking and functional assays
strongly suggest that VCE-003.2 is a PPARγ partial
agonist that mediates biological functions but acting
through canonical and alternative PPARγ pathways.
Thus, it is not surprising to find that the blockade of
PPARγ with either GW9662 or T0070907 did not
prevent some of the effects of VCE-003.2, even they
were potentiated in some cases. Accordingly, it has been
shown that T0070907 enhances the ability of some
partial PPARγ agonists such as BVT.13 and nTZDpa to
bind the PPARγ coactivator TRAP220 [20]. Equivalent
data have been found for other biological activities
[36, 37], as has been indicated in the “Results” section.
There is experimental evidence in the literature indi-
cating that persistent LPS exposure in BV2 cells causes a
downregulation in the expression of PPARγ receptors,
which has been proposed to be elicited by elevated
TNF-α synthesis [34, 35], as well as by an expected
upregulation of NFκB signaling [55]. We found that
VCE-003.2, as well as RGZ, induces the expression of
PPARγ at the protein level and prevented LPS-induced
downregulation of this protein. Since PPARγ gene
expression is also upregulated by PPARγ ligands, our re-
sults further support a role for PPARγ as a major path-
way activated by VCE-003.2. Nevertheless, we cannot
exclude that VCE-003.2 induces PPARγ-independent
effects and preliminary results indicates that this CBG
derivative is also a dual inhibitor of the FAAH and
MAGL activity (unpublished data) and is also an antioxi-
dant (see Additional file 3). Thus, further research is
warranted to investigate the mechanism of action of
VCE-003.2 in neuroinflammatory conditions and to fully
understand the differences between the in vivo (LPS-le-
sioned mice) and in vitro results regarding blockade by
classic PPARγ antagonists. A possible explanation may
be based on the differences between in vivo (complete
cytoarchitecture) and in vitro (isolated cell populations)
models. In this sense, it has been shown that serotonin
metabolites, an important neurotransmitter with a
potential relevant role in PD, binds and activates PPARγ
[56], and it will be of interest to analyze the potential
synergistic or additive activity of serotonin and VCE-
003.2 on the PPARγ pathway. If the serotonin tone is
lowered in PD patients, it will be possible to increase
this tone in the presence of VCE-003.2, at least acting
on PPARγ signaling.
Lastly, our study also addressed an additional objective
as investigating the neuroprotective potential of VCE-
003.2 dependent on its antioxidant profile in an experi-
mental model of PD having poor microglial reactivity
(see Additional file 3). We used 6-hydroxydopamine-
lesioned mice, in which, as mentioned above, several
antioxidant phytocannabinoids, such as cannabidiol, Δ9-
tetrahydrocannabinol and Δ9-tetrahydrocannabidivarin,
had been able to preserve TH-positive neurons in the
substantia nigra through effects dependent on their
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cannabinoid receptor-independent antioxidant properties
[7, 8, 21]. Our data indicated that this phytocannabinoid
derivative was also beneficial in 6-hydroxydopamine-
lesioned mice. However, contrarily, to the model of LPS
lesions, its effects were more evident at the behavioral
level (by improving motor impairment) than at the
histopathological level. In fact, we were unable to detect a
relevant effect on the preservation of TH-positive neurons
and we found the expected lack of glial reactivity (see
Additional file 3). We assume that these effects may
reflect a certain protective effect based on the antioxidant
activity of VCE.003-2, but it is possible that they simply
reflect a mere symptom-relieving action not associated
with preservation of nigral neurons.
Conclusion
In summary, we have demonstrated that VCE-003.2 is
neuroprotective against inflammation-driven neuronal
damage in an in vivo model of PD, acting through the
activation of the canonic binding site in PPARγ recep-
tors. In vitro cellular models reminiscent of the in vivo
PD pathology, however, indicated that the effects of
VCE-003.2 to limit inflammation may be also exerted
through additional mechanisms, including the possibility
that VCE-003.2 targets PPARγ by acting through two
binding sites at the LBP, one that is sensitive to
T0070907 (canonical binding site) and other that is not
affected by this PPARγ antagonist (alternative binding
site). Collectively, our data support the idea of VCE-
003.2 as a useful neuroprotective agent in PD based on
its multi-target properties.
Additional files
Additional file 1: Figure S1. Double immunofluorescence analysis of
Cd68 (in green) and TH (in red) in the substantia nigra pars compacta of
adult male mice at 3 weeks of being subjected to an intrastriatal injection of
LPS. Top panels show both immunostainings in the contralateral (lesioned)
and ipsilateral (non-lesioned) sides (scale bar = 50 μm), whereas bottom
panels show the immunostaining for both markers and the merged image
in the contralateral (lesioned) side (scale bar = 50 μm), proving the presence
of Cd68 immunostaining associated with TH-positive cells, but a complete
lack of overlapping, then demonstrating that they correspond to different
cells (TH-positive neurons versus Cd68-positive microglial cells) (PDF 757 kb)
Additional file 2: Figure S2. BV2 cells were seeded at 1 × 105 in 60-mm
dishes and 24 h later treated with RGZ or VCE-003.2 in the absence or the
presence of LPS (50 ng/mL) for 6 h and the steady state levels of endogenous
PPARγ and β-actin detected by western blot (PDF 105 kb)
Additional file 3: Supplementary information and Supplementary
Figures S3–S5. Effects of VCE-003.2 in 6-hydroxydopamine-lesioned mice
(PDF 564 kb)
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